Company: CERO
Filing Date: 2025-02-06
Form Type: 8-K
Source: 0001213900-25-010731
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-06
Form: 8-K
Item: Item 1.01
Chunk 1
---
-of-pocket expenses
in an amount up to $85,000, non-accountable expenses of up to $25,000 and has agreed to reimburse Jones for all reasonable and documented
out-of-pocket fees and expenses, including but not limited to travel and other out-of-pocket expenses in an amount not to exceed $15,000.

The
Company’s directors and executive officers agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the
sale of or otherwise dispose of any shares of common stock or other securities convertible into or exercisable or exchangeable for common
stock for a period of 90 days following the closing date of the Offering, which terms may be waived in the sole discretion of and without
notice by the Placement Agent, subject to certain exceptions. In addition, the Company has agreed to not enter into variable rate financings
for a period of 180 days following the closing date, subject to certain exceptions, or enter into any equity financings for a period
of 60 days following the closing date, subject to certain exceptions.

The
shares of Common Stock and the Warrants described above and the shares of Common Stock underlying the Warrants were offered pursuant
to the Registration Statement on Form S-1 (File No. 333-284007), as amended, which was declared effective by the Securities and Exchange
Commission on January February 5, 2025.

The
closing of the Offering is expected to occur on February 7, 2025. The Company expects to receive gross proceeds of approximately $5 million,
before deducting the estimated offering expenses payable by the Company, including the Placement Agent and financial advisory fees. The
Company intends to use the net proceeds from the Offering for advancement of its clinical programs and working capital and other general
corporate purposes.

The
foregoing summaries of the Placement Agency Agreement, the Warrants and the Purchase Agreement do not purport to be complete and are
subject to, and qualified in their entirety by, the forms of such documents, which are filed as exhibits 1.1, 4.1 and 10.1 to this Current
Report on Form 8-K, respectively, which are incorporated by reference.

Item
8.01 Other Events.